Real-world outcomes following switching from anti-TNF reference products to biosimilars for the treatment of psoriasis

Tumor necrosis factor (TNF) inhibitors improved clinical outcomes for patients with psoriasis but are limited by their high cost. There are several biosimilar options approved for the treatment of psoriasis which provides a lower-cost alternative and the potential to increase treatment availability...

Full description

Bibliographic Details
Published in:	Journal of Dermatological Treatment
Main Authors:	Rachel C. Ruda, Katherine A. Kelly, Steven R. Feldman
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Subjects:	psoriasis tnf-inhibitor biosimilar biological agents
Online Access:	http://dx.doi.org/10.1080/09546634.2022.2140569

Similar Items

Switching to an Infliximab Biosimilar Was Safe and Effective in Dutch Sarcoidosis Patients
by: Bas J. M. Peters, et al.
Published: (2021-02-01)

The Place of Biosimilars in the Therapeutic Strategy in Patients with Moderate-to-Severe Plaque Psoriasis
by: Aleksandra Lesiak, et al.
Published: (2025-06-01)

Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
by: Steven R. Feldman, et al.
Published: (2024-12-01)

Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?
by: Roy Fleischmann, et al.
Published: (2020-01-01)

Biosimilars
by: Emel Bülbül Başkan
Published: (2022-04-01)

Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
by: Alexandra Azevedo, et al.
Published: (2018-09-01)

Efficacy and safety evaluations of adalimumab biosimilars in the treatment of psoriasis
by: Changkun Li, et al.
Published: (2023-12-01)

Severe paradoxical generalized pustular psoriasis induced by adalimumab biosimilar successfully treated with brodalumab
by: Angela Fico, et al.
Published: (2025-05-01)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
by: Claudia Fabiani, et al.
Published: (2019-12-01)

Ustekinumab Biosimilars
by: Elena Carmona-Rocha, et al.
Published: (2024-11-01)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
by: Evelien Moorkens, et al.
Published: (2020-10-01)

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

Eosinophilia Induced by Biosimilar Adalimumab (CinnoRA) in a Patient with Psoriasis and Psoriatic Arthritis: A Case Report
by: Saedpanah R, et al.
Published: (2025-09-01)

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study
by: Johan Sieborg, et al.
Published: (2025-03-01)

Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Zhen Zeng, et al.
Published: (2024-07-01)

An exploration of biosimilar TNF-alpha inhibitors uptake determinants in hospital environments in Italy, Portugal, and Spain
by: Teresa Barcina Lacosta, et al.
Published: (2023-01-01)

A review of biosimilars in psoriasis: impacts on efficacy, safety, access, and a first-hand look at biosimilar cost savings within the department of veterans affairs
by: Rebecca Reese, et al.
Published: (2024-12-01)

Commentary: Anti-TNFα in inflammatory bowel disease: from originators to biosimilars
by: Yingjie Liu, et al.
Published: (2025-07-01)

Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: Results of a retrospective French multicenter study
by: Guillaume Larid, et al.
Published: (2022-10-01)

Optimizing development of anti-TNFα biosimilars based on 10 years’ experience
by: Cecil Nick
Published: (2025-02-01)

The effectiveness of switching from an originator biological agent to its biosimilar, or vice versa, for ankylosing spondylitis in real clinical practice
by: K. V. Sakharova, et al.
Published: (2020-11-01)

Patent and Regulatory Landscape of Biosimilars in the United States and Europe: Implications for Advancing the Domestic Biosimilar Industry with a Focus on Anti-TNF-α Biopharmaceuticals
by: Tae-Kwon Kim, et al.
Published: (2025-06-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data
by: Marko Krstic, et al.
Published: (2024-04-01)

Cost per responder of adalimumab biosimilars versus methotrexate in patients with psoriasis: a real-life experience
by: Martina Maurelli, et al.
Published: (2023-12-01)

Severe plaque psoriasis with coexisting cicatricial alopecia treated with adalimumab – case report
by: Dorota Krasowska, et al.
Published: (2014-03-01)

Biosimilars: presumption of guilt
by: Marina Vladimirovna Shestakova, et al.
Published: (2011-12-01)

Real-World Experience with an Adalimumab Biosimilar (ABP 501) in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis in Europe: Results from the Adelphi Disease Specific Programme
by: Ran Jin, et al.
Published: (2025-03-01)

Switching from Reference to Biosimilar Products: An Overview of the European Approach and Real-World Experience So Far
by: Anna La Noce, et al.
Published: (2018-09-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Summary of Research: Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial
by: Alan Menter
Published: (2023-10-01)

Efficacy of switching from originator adalimumab to biosimilar adalimumab-AACF in patients with axial spondyloarthritis: a 12-month observational study
by: Fanny Alcira Reyes Neira, et al.
Published: (2025-02-01)

Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy – a delphi methodology
by: Tiago Torres, et al.
Published: (2025-12-01)

Relationship between psoriasis severity degree and TNF-α levels in patients with psoriasis in combination with arterial hypertension
by: V. P. Fedotov, et al.
Published: (2015-06-01)

Anti-TNF alpha-induced paradoxical psoriasis treated with topical roflumilast 0.3%
by: Edith Hanna, MD, et al.
Published: (2024-06-01)

Analysis of Drug Utilization in Patients with Psoriasis: A Real-World Retrospective Study Among the Italian Population
by: Perrone V, et al.
Published: (2023-03-01)

CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
by: David M. Pariser, et al.
Published: (2025-03-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019-07-01)

Generalised pustular psoriasis – a case report and review of therapeutic approaches
by: Agnieszka Osmola-Mańkowska
Published: (2014-11-01)

Anti-TNF-Alpha-Induced Psoriasis – An Unusual Paradox
by: Neel Sharma, et al.
Published: (2009-11-01)